Opinion

Video

The Pathophysiology of Psoriasis as a Target for Treatment

Expert dermatologist Dr Linda Stein Gold discusses the pathophysiology of psoriasis as target for treatment.

Linda Stein Gold, MD: Traditionally we've used broad immunosuppressants to treat our psoriasis patients, but as we've come to understand the pathogenesis of disease, we're able to…target our treatments to better hit those abnormalities in the immune system, which are underlying the pathogenesis of disease. We know that the inflammatory pathway that drives psoriasis is…modulated by proinflammatory cytokines and cytokine signaling. So we don't know exactly what starts off this whole process, but something happens that causes keratinocytes to release antimicrobial peptides and pro-inflammatory signals. These call into action these inflammatory cells, including plasma dendritic cells. They secrete a type 1 interferon, which activates a number of cells, including myeloid dendritic cells, and this cell secrete IL-23 and IL-12. Now, it's IL-23 that…simulates the differentiation of T cells to form TH-17 cells. And these TH-17 cells produce IL-17, and IL-17 is that cytokine that's important in the end organ damage. And if we think of the end organs being the skin and the joints, this causes the signs and symptoms of psoriasis. So, when we take a step back and look at what is the key axis that really drives psoriasis and psoriasis pathogenesis, we understand that it's this IL-23 and IL-17 pathway that really is at the core of psoriasis pathogenesis.

Transcript is AI-generated and edited for clarity and readability.

Related Videos
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
Wendy Wright, DNP, an expert on fibromyalgia
Melodie Young, ASN, RN: Updates on Therapies for Pediatric Patients with Psoriasis, PsA
Wendy Wright, DNP, an expert on fibromyalgia
Harnessing Patient Insights: The Role of PROs in Managing Psoriasis and Psoriatic Arthritis
Wendy Wright, DNP, an expert on fibromyalgia
1 KOL is featured in this series.
1 KOL is featured in this series.
Dennis M. Marcus, MD , an expert on neovascular AMD
© 2024 MJH Life Sciences

All rights reserved.